Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG ‐LU16‐07

ConclusionsDurvalumab and tremelimumab demonstrated clinical benefit with a prolonged survival and manageable toxicity profile in patients with recurrent or metastatic PSC.

Source: Thoracic Cancer - October 7, 2020 Category: Cancer & Oncology Authors: Miso Kim, Bhumsuk Keam, Chan ‐Young Ock, Se Hyun Kim, Yu Jung Kim, Sun Min Lim, Jin‐Soo Kim, Tae Min Kim, Sook‐Hee Hong, Mi Sun Ahn, Seong Hoon Shin, Eun Joo Kang, Dong‐Wan Kim, Sun‐Wha Im, Jong‐Il Kim, Jong Seok Lee, Joo‐Han Tags: ORIGINAL ARTICLE Source Type: research